Jeff M. Michalski, MD, MBA, FASTRO provides an overview of the novel decision making approach he’s developed as an extension of the clinical-genomic nomogram developed by Spratt et al. (JCO 2018). Dr. Michalski presents a case study of a 46 year-old man with Gleason 4+3=7 prostate cancer demonstrating how he uses the nomogram to help address the dilemma surrounding ADT-related decisions in newly-diagnosed intermediate risk prostate cancer patients.

свернуть